Y-3 for Injection in the Treatment of Acute Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 998 participants.

Also called NCT06517173

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 998 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06517173
Other papers using this trial's data
  • Loberamisal for Acute Ischaemic Stroke (LAIS): a multicentre, randomised, double-blind, parallel, placebo-controlled phase III clinical trial Stroke and vascular neurology, 2026-08-27 DOI, PubMed 41344725, PMC13540280 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06517173. Randomized; triple masking; primary purpose treatment. Start 2024-07-24 (actual); primary completion 2025-04-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Y-3 for Injection in the Treatment of Acute Ischemic Stroke
Acronym
LAIS
Condition
Acute Ischemic Stroke
Intervention (Drug)
Y-3 for injection
Intervention (Drug)
Placebo control group
Lead sponsor
Beijing Tiantan Hospital (class: other)
Collaborator
Neurodawn Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06517173
Content hash
149b8bbec848b9967b250dde45fc1e276cc049b9f5ce1cd1fb15ac9fccad9ea1